University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Interactions
Database of Antiretroviral Drug Interactions

Interactions with Isoniazid (INH, others) and Antiretrovirals

Antiretroviral (ARV)Dose of ARVDose of IsoniazidEffect on ARV LevelsEffect on Isoniazid LevelsPotential Clinical EffectsMechanism of InteractionManagement
Dolutegravir753
(Tivicay)
50 mg once daily15 mg/kg + rifapentine 900 mg once weeklyDTG AUC decreased 46%; Cmin decreased 74%INH AUC increased 67-92% in 2/4 subjects. Rifapentine no significant change.Potential adverse effects of isoniazid (flu-like symptoms, nausea, vomiting, and fever)-

Do not coadminister

Indinavir16
(IDV)(Crixivan)
800 mg Q8H x 1 week300 mg QD x 1 weekNo significant changeNo significant change--

No dose adjustment necessary

"-" indicates that there are no data available
 16:Crixivan [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; Oct 2005.
 753:Brooks KM, Pau AK, George JM, Kellogg A, McLaughlin M, McManus M, Hadigan C, Kovacs JA, Kumar P. Early termination of a PK study between dolutegravir and weekly isoniazid/rifapentine. Conference on Retroviruses and Opportunistic Infections 2017. February 13–16, 2017. Seattle, Washington. Abstract 409a.